Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT06193304
- Locations
- 🇺🇸
Covance Clinical Researsh Unit, Evansville, Indiana, United States
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06192563
- Locations
- 🇮🇹
Investigational Site Number: 002, Bologna, Italy
🇮🇹Investigational Site Number: 006, Brescia, Italy
🇮🇹Investigational Site Number: 004, Firenze, Italy
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06191315
- Locations
- 🇫🇷
Investigational Site Number : 2500004, Nice, France
🇺🇸Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona, United States
🇺🇸Newport Children's Medical Group - Newport Beach- Site Number : 8400023, Newport Beach, California, United States
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
- Conditions
- Acid Sphingomyelinase DeficiencyNiemann-Pick Diseases
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT06192576
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Pulse InfoFrame US Inc., Philadelphia, Pennsylvania, United States
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06188325
- Locations
- 🇺🇸
M.D.Covance Clinical Research Unit 1341 W, Dallas, Texas, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 547
- Registration Number
- NCT06181435
- Locations
- 🇨🇳
Investigational Site Number : 1560029, Hangzhou, China
🇨🇳Investigational Site Number : 1560007, Jinan, China
🇮🇹Investigational Site Number : 3800022, Vicenza, Italy
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 302
- Registration Number
- NCT06169527
- Locations
- 🇫🇷
Investigational Site Number: 2500040, Le Mans, France
🇫🇷Investigational Site Number: 2500041, Amiens, France
🇫🇷Investigational Site Number: 2500037, Angers, France
Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: SAR153191-P3 drug productDrug: SAR153191-P2 drug productDrug: SAR153191-C1F3 drug product
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 53
- Registration Number
- NCT06159452
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- Conditions
- Hemophilia A
- Interventions
- Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA)Biological: Antithrombin concentrate (ATIIIC)Biological: Emicizumab
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06145373
- Locations
- 🇨🇳
Investigational Site Number : 1580001, Taipei, Taiwan
A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
- Conditions
- Gaucher's Disease Type I
- Interventions
- Drug: [14C]-Genz-112638
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT06143904